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1. Introduction  
Pancreatic ductal adenocarcinoma (PDAC) is by far the most common type of tumor in the 
exocrine pancreas, accounting for 85% to 100% of all malignant pancreatic tumors (Kloppel 
et al., 2004). During the last 30 years, little improvement in the prognosis of patients with 
PDAC has been achieved (Jemal et al., 2009). A better understanding of the biological nature 
of this neoplasm might improve the prognosis of patients. For this purpose, permanent 
cultured cell lines are helpful, since their convenience of use facilitates a variety of 
experiments (Ku et al., 2002). However, the amount of viable tumor-derived material is 
limited. The majority of research in PDAC has been done in a few cell lines; only 19 
pancreatic carcinoma cell lines are broadly available for research. In addition to their small 
number, permanent cell lines have another disadvantage: the long culture times leave the 
cells prone to genetic drift (Kato et al., 1999; McQueen et al., 1991).  
To obtain a greater phenotypic heterogeneity of the disposable cell lines, and to circumvent 
the use of “old” cell lines, it is advantageous for research laboratories that focus on 
pancreatic cancer to establish their own primary carcinoma cell lines (Ruckert et al., 2011). 
Before using these cell lines in basic research, the origin of the cell line should be confirmed 
to exclude cross-contamination by existing cell lines. This is important, because some 
studies suggest that 15–20% of the cell lines used in experiments have been misidentified or 
contaminated with another cell line, which is also true for primary cell lines (Cabrera et al., 
2006; Drexler et al., 1999). A characterization of the cell lines is further necessary to analyze 
and document the typical biochemical and pathophysiological features of the tumor cell 
lines (Henderson et al., 1996). In the present article we give information on how to isolate 
and characterize primary pancreatic cancer cell lines.  
2. Techniques for the isolation of primary pancreatic cancer cell lines  
The principle of tissue culture was established by Wilhelm Roux in the 19th century. 
However, it took nearly 60 years before the establishment of the first human cancer cell line 
(Gey et al., 1952). The first report on the culture of pancreatic cancer cell lines was in l963 
(Dobrynin, 1963). Cells that are cultured directly from a subject are known as primary cell 
lines and different techniques have been used to establish such pancreatic cancer cell lines. 
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Some of these primary cells can be cultured successfully over a long time period and are 
then named permanent or immortal cell lines.  
The most frequent used techniques are explant culture (where the culture grows from a 
solid tumor sample), xenografting, enzymatic digestion and culture of malignant bodily 
fluids. In the following, we describe these techniques in detail.  
2.1 Explant cultures 
The two most frequently used explant culture techniques are the “mechanical dissociation” 
and the “outgrowth method”. To obtain sterile conditions, the tumor specimen should be 
rinsed three times in wash medium.  
Most scientist use the mechanical dissociation to establish pancreatic cancer cell lines (Table 
1). In this technique after washing, the specimen is transferred to a sterile petridish and cut 
up into smaller pieces about 1-2 mm3 using sterile scalpel and forceps. The fragments and 
the spilled cells are then placed in a tissue culture flask and medium is added. The 
production of proteolytic factors (Diamantidis et al., 2008; Mahadevan et al., 2007) and 
augmented cell motility (Hotz et al., 2007; Rückert et al., 2010) enables pancreatic cancer 
cells to actively leave the tissue fragment. Complexes of tumor cells can be seen within the 
medium after 24 h (Figure 1, C and D). The presence of these “STC´s” (small trabecular 
complex) is generally a good predictive parameter for the successful isolation of primary 
tumor cell lines and under standard cell culture conditions cancer cell colonies will grow, as 
well as other contaminating cell types such as fibroblasts or lymphocytes (Rückert et al., 
2011).  
The other explant culture technique is the outgrowth method. As in the mechanical 
dissociation- technique, little pieces of the solid tumor are produced by dissection of the 
tumor sample with an sterile scalpel. Those little fragments are placed within a 6-well plate 
and left to dry until the pieces stick on to the surface. Medium is then added cautiously. 
Tumor cells as well as fibroblast will grow out of the tissue fragment (Figure 1, A and B; for 
a pictured tutorial see Rückert et al., 2011).   
2.2 Xenografts 
Xenografting of tumor samples into athymic mice is a way to establish pancreatic tumor 
lines with a good success rate and is frequently used by scientist for this purpose (Hotz et 
al., 2000). By repeated passages of the tumor lines in nude mice the cells are said to become 
more aggressive. Some of these tumor lines are used as source for the establishment of cell 
lines by either explant cultures or enzymatic digestion (Dexter et al., 1982; Yachida et al., 
2011) (Table 1).   
2.3 Enzymatic digestion 
Enzymatic digestion can be used to free cancer cells from adherent connective tissue and 
produce a suspension of cells. For this purpose different enzymes are used, such as trypsin 
(Kaku et al., 1980) or collagenase type IV (Chifenti et al., 2009; Kalinina et al., 2010). 
However, this method is laborious and rarely used to establish pancreatic cancer cell lines 
(Table 1).   
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Author and 
year 
Name Method used Medium Characterisation 
(Dobrynin  
et al., 1963) 
CaPa 
Explant 
culture 
Medium 199, 5% 
human serum, 5% FCS 
M, DD, chr 
(Lieber 
et al., 1975) 
Panc-1 
Explant 
culture 
DMEM, 10% FCS 
M, DD, chr, xeno, 
FA 
(Owens  
et al., 1976) 
Hs 700T Enzymatic 
digestion 
DMEM, 10% FCS 
M, DD, chr, 
plating efficiency HS 766T 
(Yunis  
et al., 1977) 
MIA PaCa-
2 
Explant 
culture 
DMEM, 10% FCS, 2.5% 
horse serum 
M, DD, chr, HC, 
FA, EM 
(Akagi & 
Kimoto, 1977) 
HCG-25 
Ascites w/ 
medium 
RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
HC, FA, EM, 
plating efficiency 
(Fogh  
et al., 1977) 
Capan-1 n.n. RPMI 1640, 15% FCS 
M, DD, HC, xeno, 
FA 
(Grant  
et al., 1979) 
Ger 
Explant 
culture 
(Ham's F12 + Eagle's) or 
DMEM, 10% FCS, 
amino acids, 1 mM 
glutamine,  
AA, 50 tzg/ml soya-
bean trypsin  
inhibitor 
M, DD, chr, xeno, 
FA,TM 
(Kaku  
et al., 1980) 
QCP-1 
Enzymatic 
digestion  
Medium 199, 10% FCS 
M, DD, chr, HC, 
FA 
(Morgan  
et al., 1980) 
COLO 357 
Explant 
culture 
RPMI 1640, 20% FCS 
M, DD, chr, HC, 
FA, plating 
efficiency 
(Chen  
et al., 1982) 
AsPC-1 
Ascites w/ 
medium 
RPMI 1640, 10% FCS 
M, HC, chr, xeno, 
FA 
(Metzgar  
et al., 1982) 
HPAF 
Ascites w/ 
medium 
EMEM, 10% FCS xeno 
(Dexter, 1982) 
RWP1 
Xenograft 
RPMI 1640, 20% FCS, 
buffered 
  
M, DD, chr, HC, 
xeno, FA,  
plating efficiency RWP2 
(von Bulow  
et al., 1982)  
PancTuI-I n.n. n.n.   
(Kyriazis 
et al., 1983) 
SW-1990 
Explant 
culture 
L-15-CI 
M, DD, chr, HC, 
xeno, FA, plating 
efficiency 
(Yamaguchi  
et al., 1983) 
HPC-Y1 n.n. RPMI 1640, 10% FCS M, xeno, TM 
(Okabe  
et al., 1983) 
T3M-4 Xenograft F10, 15% FCS, AA M, DD, chr, HC 
(Kyriazis  
et al., 1986) 
Capan-2 n.n. 
RPMI 1640, 15% FCS, 
AA 
M, DD, chr, HC, 
xeno, FA, plating 
efficiency 
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Author and 
year 
Name Method used Medium Characterisation 
(Yamada  
et al., 1986) 
PSN-1 Xenograft RPMI 1640, 10% FCS M 
(Yamaguchi  
et al., 1986) 
HPC-YT n.n. RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
FA 
(Tan et al., 1986) BxPC-3 
Explant 
culture 
RPMI 1640, 20% FCS, 
buffered 
M, DD, chr, HC, 
xeno  
(Kobari  
et al., 1986) 
PK-1 
Explant 
culture 
MEM, 20% FCS 
M, DD, chr, HC, 
xeno, TM, 
doubling time 
PK-8 
PK-9 
PK-12 
PK-14 
PK-16 
(Iwamura  
et al., 1987) 
SUIT-2 
Explant 
culture 
DMEM, 5% FCS 
M, DD, xeno, TM, 
EM  
(Sujino 
et al., 1988) 
JHP-1 
Ascites w/ 
medium 
 n.n. 
M, DD, chr, xeno, 
TM, plating 
efficiency 
(Drucker  
et al., 1988) 
SU.86 
Explant 
culture 
RPMI 1640, 20% FCS 
M, DD, HC, chr, 
xeno, TM 
(Nagata  
et al., 1989) 
FA6 Xenograft RPMI 1640, 10% FCS FA 
(Frazier  
et al., 1990) 
MDA 
Panc-3 
Explant 
culture 
(L-15 + DMEM), 16 
kg/ml glutathione, 5 
kg/rnl insulin, 5 pg/ml 
transferring, 5 ng/ml 
selenium,  
5 ng/ml EGF,  
10% FCS, AA 
M, DD, chr,  
HC, EM  
(Fujii  
et al., 1990) 
SOJ 
Explant 
culture 
RPMI 1640, 10% FCS 
M, DD, chr, xeno, 
TM 
(Schoumacher 
et al., 1990) 
CFPAC-1 
Explant 
culture 
RPMI 1640, 10% FCS IHC, xeno, FA 
(Ikeda  
et al., 1990) 
KP-1N 
Xenograft Daigos T, 10%FCS IHC, xeno, TM KP-2 
KP-3 
(Yamaguchi  
et al., 1990) 
HPC-Y0 
Explant 
culture  
RPMI 1640, 10% FCS 
M, DD, IHC,chr, 
xeno, FA 
HPC-Y1 
HPC-Y5 
HPC-Y9 
HPC-Y11 
HPC-Y15 
HPC-YP 
HPY-YS 
HPC-Y25 
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Author and 
year 
Name Method used Medium Characterisation 
(Chen  
et al., 1990)  
PC-1 
Xenograft Ham´s F12, 15% FCS 
M, DD, chr, IHC, 
xeno, TM PC-2 
(Elsasser  
et al., 1992)  
PA-TU-
8988S Explant 
culture 
DMEM, 10% FBS, 10% 
Horse serum, 2 mM 
glutamine, AA 
M, DD, chr, HC, 
xeno, EM PA-TU-
8988T 
(Nishimura  
et al., 1993) 
HuP-T3 
Ascites w/ 
medium 
MEM, 10% FBS, 1% 
amino acids, 1% 
sodium pyruvate  
M, DD, xeno, TM 
HuP-T4 
(Elsasser  
et al., 1993) 
PA-TU-
8902 
Explant 
culture 
DMEM, 10% FCS, 2 
mM glutamine 
M, DD, chr, IHC, 
xeno, TM, EM 
(Kalthoff  
et al., 1993) 
PT45 n.n. n.n.   n.n. 
(Vila  
et al., 1995) 
IMIM-PC-1 
Explant 
culture 
E4, 10% FCS 
M, IHC, TM, FA 
  
IMIM-PC-2 
SK-PC-1 
SK-PC-3 
(Heike  
et al., 1995) 
MZ-PC-1 
Pleural 
effusion w/ 
medium 
CMRL, 15% FCS, 2 mM 
glutamine, 1% amino 
acids 
M, IHC, xeno, EM  
(Lehnert  
et al., 1999) 
A818 
Explant 
culture 
RPMI 1640, 10% FCS,  
2 mM glutamine,  
1 mM sodium 
pyruvate, AA 
TM, FA 
(Kato  
et al., 1999) 
KMP-1 
Explant 
culture  
RPMI 1640 + Ham’s 
F12, 20% FCS, AA  
M, DD, chr, IHC, 
xeno, TM, seeding 
efficiency 
KMP-2 
KMP-3 
KMP-4 
KMP-5 
KMP-6 
(Hou  
et al., 1999) 
PC-EN Xenograft n.n. 
M, DD, chr, mut, 
IHC, xeno, TM 
(Fralix  
et al., 2000) 
UK Pan-1 
Explant 
culture 
DMEM, 10% FCS 
M, DD, chr, mut, 
xeno, FISH 
(Ku et al., 2002) 
SNU-213 
Explant 
culture 
ACL-4, 5% FCS 
M, DD, chr, mut, 
IHC  
SNU-324 
SNU-410 
SNU-494 
(Eisold  
et al., 2004) 
FAMPAC 
Explant 
culture 
RPMI 1640, 10% FCS, 
AA 
M, DD, chr, mut, 
xeno, TM 
(Kawano  
et al., 2004) 
SUIT-4 
Ascites w/ 
medium 
DMEM, Ham´s F12, AA 
M, DD, chr, mut, 
IHC, xeno, FA 
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Author and 
year 
Name Method used Medium Characterisation 
(Starr  
et al., 2005) 
p34 
Pleural 
effusion w/ 
medium 
DMEM, 10% FCS, 2 
mM glutamine, AA 
M, DD, chr, IHC, 
xeno, FA 
(Kong  
et al., 2007) 
SPH 
Ascites w/ 
medium 
n.n. 
M, DD,  
chr, xeno, 
TM 
(Chifenti  
et al., 2009) 
PP78 
Enzymatic 
digestion  
RPMI 1640, 
1% glutamine,  
10% FCS, AA 
M, DD,  
STR, chr,  
mut, IHC,  
FA 
PP109 
PP117 
PP161 
(Kalinina  
et al., 2010) 
PaCa 5061 
Enzymatic 
digestion  
RPMI 1640,  
10% FCS, 
AA, 50 nmol/ml 
transferrin,  
0.01 μg/ml insulin, 
0.01 μg/ml EGF,  
0.01 μg/ml basic FGF 
M, DD,  
IHC, xeno, FA, 
TM, FISH 
(Rückert  
et al., 2011)  
PaCaDD-43 
Explant 
culture 
Dresden-Medium  
M, DD, STR, mut, 
FA  
PaCaDD-60 
PaCaDD-119 
PaCaDD-135 
PaCaDD-137 
(Yachida  
et al., 2011) 
a99 Xenograft DMEM, 20% FCS 
M, DD,  
chr, mut,  
xeno, colony 
formation  
(DD= doubling rate/ growth curve; M= morphology; STR= standard tandem repeat/DNA-fingerprint; 
chr= chromosomal analysis; mut= mutational analysis; xeno= xenograft; FA= functional analysis;  
HC= histochemistry; IHC= immunohistochemistry; EM= electron microscopy, TM= tumor marker; 
AA= antibiotics).  
Table 1. Human pancreatic tumor cell lines (adapted from Iwamura & Hollingsworth,  
1998). This list is not exhaustive. Some of the cell lines are available at ATCC 
(www.lgcstandards-atcc.org) or the German Collection of Microorganisms and Cell 
Cultures (www.dsmz.de)  
2.4 Processing of malignant pleural effusion or ascites 
This method is frequently used to obtain primary cancer cell lines. Although the success rate 
is not higher than in other methods many scientist favour this technique as material is easily 
obtainable. For establishing cancer cell lines with this method, bodily fluids are added to 
variable amounts of cell culture medium (Akagi et al., 1977; Chen et al., 1990; Nishimura et 
al., 1993) (Table 1).  
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Fig. 1. Typical morphology of a primary pancreatic cancer colony (A). Fibroblasts growing 
out of a tissue fragment (B). Figures C and D depict complexes of cancer cells (full arrow) 
which the author calles “STC´s” (small trabecular complex). In (C) there is also a cluster of 
mesenchymal cells (interrupted arrow).  
2.5 General remarks on the establishment of primary cell lines 
The processing of samples should be as fast as possible. The success rate for the 
establishment of cell lines is considerably shortened if processing starts more than 2 hours 
after harvesting of the sample.  
Parenchymal cells in culture are generally obvious due to their close cell-cell contacts and 
their tendency to grow in colonies (Figure 1, A). However, parenchymal cells are often 
overgrown by cells from the stromal compartment (Figure 1, B). Those fibroblasts can be 
removed by different techniques. One possibility is to mechanically remove fibroblasts by a 
sterile cannula under phase contrast microscope. Another method uses a solution of trypsin 
to enzymatic remove fibroblasts. This enzymatic removement is possible because tumor 
cells adhere much more firm to the surface than fibroblasts do. 
The successful establishment of primary cell lines is often impeded by contamination by 
fungi and bacteria. For this purpose we advise to always use antibiotics within the cell 
culture media. A way to protect cell lines from fungal infection is reported in Rückert et al, 
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2011. Cell lines should be cryoconserved early and often during the early passages. As a 
general rule, cultures of pancreatic tumor cell lines should be split at high density (l : 2) 
(Iwamura et al., 1998; Rückert et al., 2011). 
3. Cell culture conditions and medias  
The majority of pancreatic cancer cell lines are grown in vitro in a basic culture medium such 
as DMEM or RPMI 1640 substituted with foetal calf serum (FCS) in varying percentages 
(Table 1). However, there are also successful isolations using other media. Generally, after a 
primary cell culture is established it should be assessed if growth might be optimized by a 
different media and/or a different ratio of FCS. Some pancreatic tumor cells can be adapted 
to growth in reduced serum (0.5% or less) or serum free conditions.  
Cell cultures are generally maintained at 37°C in a humidified atmosphere of 5% CO2 in air, 
and the medium should be replaced every 3 d in established cultures.  
To guarantee the availability of primary cell lines for the further experiments, all cell lines 
should be cryoconserved. Storage of cryotubes should always be performed in liquid nitrogen.   
4. Characterisation of primary tumor cell lines  
Characterization of primary cell lines should be conducted to proof the origin from the parent 
tumor and to proof the absence of cross-contamination. Only by this the researcher can be sure 
that in vitro studies with a certain cell line can be related to a distinct tumor and its 
clinicophysiological properties. Most malignant tumors are heterogeneous in morphology 
and biological properties, e.g. degree of differentiation, malignant transformation, and 
metastatic properties. This fundamental facet of all solid tumors is called tumor 
heterogeneity (Heppner, 1984). Therefore it is essential to further define the cytostructural and 
pathophysiological characteristics of the cell line.  
For these purposes different standards have been defined, which will be further explained 
below (Henderson & Kirkland, 1996; Iwamura & Hollingsworth, 1998).  
4.1 Morphology and cytostructural characteristics 
4.1.1 Growth pattern  
Pancreatic tumors are generally categorized according to morphological criteria as grades of 
differentiation and invasiveness. Many cell lines exhibit morphological characteristics that 
are consistent with the grades of differentiation reported for the tumor from which the cell 
line was derived. In cell lines, morphology is normally assessed by phase contrast 
microscopy, but some authors also use electron microscopy or histochemical staining. 
Features that should be described are: 
- the growth pattern (e.g. epithelial, disorganized, mesenchymal) 
- size of the cells (e.g. homogenous, inhomogenous, small, big) 
- form of the cell (e.g. round, polygonal, elongated, swirly) 
- size and form of the nucleus (e.g. small, big, ovoid, round) 
Some examples of growth patterns of primary cells are given in Figure 2.   
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Fig. 2. Examples of the morphology and growth pattern of the primary carcinoma cell lines 
from our research lab as seen with phase contrast microscopy (Details from 40x, pictures by 
Felix Rückert).   
www.intechopen.com
 Pancreatic Cancer – Molecular Mechanism and Targets 
 
268 
4.1.2 Immunohistochemistry 
Cell surface antigen characteristics can be used to discriminate pancreatic cancer cells from 
contaminating cell types like stromal and immune cells. The immunohistochemical 
phenotype can be compared to the native tumor tissue and thereby further proof its origin. 
Typical markers for pancreatic cancer are CK 8/18, E-cadherin, ezrin, p53, SMAD4, and 
Vimentin (Rückert et al., 2011). 
4.2 Pathophysiological characteristics 
4.2.1 Doubling time 
The doubling time is an important feature of each cell line, because it can be correlated with 
an important pathophysiological parameter: aggressive growth. Furthermore, conclusion 
can be drawn on how often medium should be changed and in which ratio cell lines should 
be split.  
The cell doubling time can be determined by plating a certain number of viable cells in to a 
well. Cells should then be counted at 24 h intervals for 7 d in triplicate. The doubling time of 
the cell population can then be calculated from the logarithmic growth curve by the 
following formula: 
ϑ = lgN - lgN0/lg2 (t-t0), 
with doubling time = 1/ ϑ 
Of course there are other possibilites to define the growth rate e.g. BrdU-staining or ki-67 
staining.   
4.2.2 Tumorigenicity 
One notable feature of pancreatic cancer, which is amenable to study through the use of cell 
lines, is invasiveness and metastasis. Tumorigenicity can be measured by assessing the 
tumor formation of cell lines in athymic mice (Henderson & Kirkland, 1996). This can be 
done by orthotope (pancreas) or ectope (subcutaneous) injection of tumor cells. The number 
of cells required ranges from 100,000 to 2,000,000 cells. Pancreatic cancer cell lines should 
form a tumor within 3-4 weeks. If the cell line has tumorigenic potential, the progression of 
tumor volume/time as well as the ability to form metastasis should be documented.   
4.3 Chromosomal and mutational analysis 
Chromosomal and mutational analyses are used to proof the origin and the uniqueness of 
each cell line. They give further evidence on the role of mutations for the pathophysiology of 
the tumor. The origin of the cell lines, however, can also be proofed by other techniques as 
microsatellite analyses (Rückert et al., 2011).  
4.3.1 Chromosomal analysis 
Chromosomal analysis has long been the standard method to proof the uniqueness of an 
certain cell line. Classically, karyotype analysis was undertaken by chromosome banding. 
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By this method numerical and structural chromosomal aberrations could be identified. 
However, the chromosomal origins of markers, subtle translocations, or complex 
chromosomal rearrangements were often difficult to identify with certainty (Schrock et al., 
1997). Because of this, new methods are recommended like the spectral karyotyping (SKY) 
or the comparative genomic hybridisation (array CGH).  
During SKY, chromosomes are hybridized simultaneously with 24 chromosome-specific 
painting probes. The measurement of defined emission spectra allows for the definitive 
discernment of all human chromosomes in different colors (Schrock, 1997). The array CGH 
is a method to analyse copy number changes (gains/losses) in the DNA content of a given 
cell. By this, gains or losses of genes in tumor chromosomes compared to normal DNA can 
be detected (Wessendorf et al., 2002).   
4.3.2 Mutational analysis 
Pre-malignant and malignant tumors evolve by clonal expansion of mutant cells that have 
either a reproductive or survival advantage over other cells in the tissue. This competitive 
advantage is acquired by the overexpression of oncogenes and inactivation of tumor 
suppressor genes. Numerous studies have found a relatively unique molecular fingerprint 
in PDAC that is comprised of frequent alterations of four genes: kRAS, p16INK4A, DPC4 and 
p53 (Bardeesy et al., 2002; Krautz et al., 2011). Because of the importance of these genes for 
the pathophysiology of PDAC the mutational analysis of these genes is recommended.   
5. Conclusion   
Basic research in cancer is absolutely dependent on cancer cell lines. The establishment of 
primary pancreatic cancer cell lines in laboratories with focus on pancreatic cancer has 
considerable advantages and can be done with reasonable expense. We hope that the 
present chapter encourages more scientists to start establishing own cell lines.   
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